Bewertung und Feedback des Lernenden für Medikamentenentwicklung von University of California San Diego
Über den Kurs
Top-Bewertungen
I am really glad to have course offered by california university . Its really helpful for me. And i am thankful to all lecturer, and teachers to explain overall drug development process.\n\nThank you!
Very well done and informative. I truly appreciate the Drug process in entirety being broken down into sections that are easy to comprehend. It is obvious the speakers were chosen for their knowledge.
251 - 275 von 390 Bewertungen für Medikamentenentwicklung
von DEVENDRA B
•good
von shekinah g
•Thank
von Basheer A N
•good
von Sohel S
•good
von Dr M
•nice
von DIVYA S K
•Nice
von 19BBT006-ANASWAR S B B B
•Nice
von Hrithikroshan
•Good
von GLORIYA V
•Good
von Uma M K
•Good
von Dhobi N
•Good
von sagiraju j s
•good
von yatam s r t
•good
von MASHETTY V
•Good
von sowjanya g
•good
von Mohammad j s
•good
von josephmary
•yes
von K V S R
•yes
von Nwando O
•E
von Sailaja B
•N
von Alan Q
•E
von Arman A
•The course content is very good and the lecturers are highly knowledgeable in their fields. However, this course is a recording from a meeting (or conference) which is a bit distracting. People asking questions and two of the female lecturers were kind of laughing / joking a lot during this serious course. Also the one who was telling about FDA (in week one) was kind of saying "Oh, I don't know that.. I am not gonna talk about that.. You should have known.." This is a course and that's not I want hear from the lecturer. I felt that this meeting was not recorded for Coursera. It seems like someone said "Oh, we have the recording of this meeting and why not sell it on Coursera?". That's why I gave 4 stars.
von ananda
•Lots of good material despite covering a broad subject area. Phase 2 lecturer and content was the highlight for me. As was the case in the related Discovery course, the Development course content is primarily drawn from a series of guest lectures as opposed to content designed from the ground up specifically for this Coursera class. An unfortunate result is rushed and/or glossed over topics. For instance, the Phase 1 guest lecturer ran out of time and skipped several slides he was planning on covering. There was also a drop off in usefulness for me in terms of Phase 3 clinical design considerations and evaluations.
von Valery T
•Thisa course was very intersting to learn more about new drug application 2 years before applying to the FDA, the week 2 and 3 clinical trials and regulatory aspects were very interesting. The format of assessment can be like content of 3/4 page and then the individual selects an option as to what to do to rectify the information. That is a more efficient process to creatively think and do the regulations job in a real world scenario. I had no hesitation in doing this course and would do it again. Very useful for my background of medical technician and analytical chemistry degrees.
von Venkat R R
•The initial sections of the course was interesting like preclinical and clinical, but some improvements needed for the later part of the course like NDA and commercialization. Overall, the content of the course needs to be updated to reflect the current pharma development process in terms of drug spending; approval time and new FDA review pathways; no, of drugs approved by each review pathway; and latest therapeutic advancements happening and how FDA views them. Hope these points will be considered in improving the course learning relevant to the current times.
Coursera Footer
